Skip to main content

Table 6 Comparison time-course serum profiles PR vs. no PR

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

m/z p-value peptide ID
1616.6366 0.007392 P-FPA
1596.189 0.011159  
872.4325 0.018308  
3215.1939 0.028873  
1631.2111 0.040931  
  1. Five peaks were significantly differential comparing NSCLC patients with a partial response versus patients with stable or progressive disease, using three time points: pre-treatment, after two cycles of treatment and end of treatment. Ordered by p-value.
  2. Abbreviation: P-FPA: phospho-fibrinopeptide A